Excelsior Biopharma's ROE % for the quarter that ended in Dec. 2025 was -19.03%. Excelsior Biopharma's PB Ratio for the quarter that ended in Dec. 2025 was 1.69.
Excelsior Biopharma's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2025 was -11.26%.
Excelsior Biopharma ROE % Adjusted to Book Value Related Terms
Excelsior Biopharma ROE % Adjusted to Book Value Historical Data
* Premium members only.
The historical data trend for Excelsior Biopharma's ROE % Adjusted to Book Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Excelsior Biopharma ROE % Adjusted to Book Value Chart
ROCO:6496 vs ZTS, UTHR: ROE % Adjusted to Book Value Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Excelsior Biopharma's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Excelsior Biopharma ROE % Adjusted to Book Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Excelsior Biopharma's ROE % Adjusted to Book Value distribution charts can be found below:
* The bar in red indicates where Excelsior Biopharma's ROE % Adjusted to Book Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROE % Adjusted to Book Value of -11.26% mean?
Excelsior Biopharma (ROCO:6496) has a ROE % Adjusted to Book Value of -11.26% as of Dec. 2025. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Excelsior Biopharma and its competitors.
Is Excelsior Biopharma's ROE % Adjusted to Book Value too high?
Excelsior Biopharma's current ROE % Adjusted to Book Value is -11.26%. Overall, Excelsior Biopharma has a GF Score™ of 51/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Excelsior Biopharma's ROE % Adjusted to Book Value compare to ZTS and UTHR?
Excelsior Biopharma's ROE % Adjusted to Book Value of -11.26% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Drug Manufacturers company?
A good ROE % Adjusted to Book Value depends on the Drug Manufacturers industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Excelsior Biopharma and its competitors. Excelsior Biopharma's current ROE % Adjusted to Book Value is -11.26%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Excelsior Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Excelsior Biopharma (ROCO:6496) is currently considered Possible Value Trap. The stock's GF Value™ is NT$35.94, compared to a current price of NT$24.90 — trading 30.7% below its estimated fair value. The current ROE % Adjusted to Book Value is -11.26%. Excelsior Biopharma's overall GF Score™ is 51/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Excelsior Biopharma (ROCO:6496), the current ROE % Adjusted to Book Value is -11.26% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Excelsior Biopharma (ROCO:6496) Overvalued in 2026?
Based on GuruFocus' analysis, Excelsior Biopharma stock appears to be undervalued.
The current stock price of NT$24.90 is trading 30.7% below its estimated GF Value™ of NT$35.94.
GuruFocus considers Excelsior Biopharma to be Possible Value Trap.
Key valuation signals for ROCO:6496:
ROE % Adjusted to Book Value: -11.26%
GF Value™: NT$35.94 vs. price of NT$24.90 (30.7% below fair value)
No single metric tells the full story. See the ROCO:6496 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Excelsior Biopharma Inc is mainly engaged in western medicines, importing and exporting of Active Pharmaceutical Ingredients, food, cosmecteuticals and development of cosmetics, research, importing, and exporting of technologies, pharmaceutical technologies transfer and cooperative development and improvement. Geographically, it derives revenue from Taiwan, China and others, with majority of revenue earned from Taiwan.
51GF Score
Get the complete analysis for ROCO:6496
ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6496 has been successfully added to your 
